
    
      Open single-center, explorative, Phase I pilot study including patients treated with AXL1717
      in addition to standard chemotherapy of gemcitabine HCL and carboplatin. Patients will be
      treated within the study for 2 treatment cycles of 3 weeks each. Survival data will be
      obtained. Tumor assessment will be conducted at baseline and then at the end of the study
      period. Concomitant supportive therapies will be allowed.
    
  